This is the one comparison on this site where the honest answer is that the two compounds are not alternatives. CJC-1295 is a GHRH analogue and ipamorelin is a growth-hormone secretagogue: they reach the pituitary through two different receptors, and the research convention is to use them together rather than choose between them. The question worth asking is what each one contributes — and, for CJC-1295, whether the DAC modification is present, which changes its behaviour far more than swapping either compound would.
| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Class | GHRH analogue (GRF 1-29) | Growth-hormone secretagogue |
| Receptor | GHRH receptor | Ghrelin receptor (GHS-R) |
| Mechanism | Amplifies the size of the GH pulse | Triggers a GH pulse |
| Half-life | Days with the DAC modification; minutes without it | Short — measured in hours |
| Selectivity | Acts on the GHRH pathway | Noted in the literature as relatively selective, with less effect on other hormones than older secretagogues |
| Human data | Early-phase pharmacology: elevated GH/IGF-1 for days after single doses (JCEM 2006) | Limited published human data; most literature is preclinical |
| Regulatory status | Investigational — never approved | Investigational — never approved |
| WADA status | Prohibited | Prohibited |
| In the Body Pharm catalogue | Yes — in the combined pen | Yes — in the combined pen |
Growth-hormone release from the pituitary is governed by more than one input. GHRH tells the pituitary to release; the ghrelin receptor provides a second, independent trigger. CJC-1295 works on the first pathway and ipamorelin on the second, which is why the literature treats them as complementary rather than competing. Comparing them for potency is a category error: one amplifies a pulse and the other initiates one, and neither substitutes for the other’s pathway.
Search interest in "CJC-1295 DAC vs no DAC" is larger than interest in either compound alone, and the distinction is real. The DAC (Drug Affinity Complex) modification binds the peptide to albumin, stretching its half-life from minutes to days — that sustained elevation is what the 2006 human pharmacology studies measured. Without DAC, CJC-1295 is essentially modified GRF 1-29 and behaves like a brief pulse-preserving signal, much closer to sermorelin. The two versions share a name and very little else in terms of exposure profile.
The pairing hypothesis is amplify-and-trigger: a GHRH analogue raises the ceiling of a pulse while a secretagogue causes the pulse to occur. Ipamorelin is the usual partner because of its reported selectivity — older secretagogues in the GHRP class have more off-target hormonal activity. Human clinical trial data for the combination specifically is limited, so the rationale is mechanistic rather than proven in outcome trials, and this page makes no claims about results.
Both compounds arrive in a single pre-loaded pen rather than as two separate items, which is why this site has no page for either one on its own. Every batch is third-party tested for identity, purity and sterility, and the certificate of analysis for the specific lot is reachable from the QR code on the pen.
Neither — they act on different receptors and are studied together. CJC-1295 amplifies a growth-hormone pulse through the GHRH receptor; ipamorelin triggers one through the ghrelin receptor. The research convention is to combine them, which is why they ship in one pen.
The DAC modification binds albumin and extends the half-life from minutes to days. With DAC, a single exposure elevated GH and IGF-1 for days in early-phase human studies. Without it, the compound behaves like a brief pulse, closer to sermorelin. It is the single largest variable in how CJC-1295 behaves.
It appears on its own in the preclinical literature, where it is noted for selectivity relative to older secretagogues. Published human data is limited, and Body Pharm supplies it only in the combined pen.
No. Neither CJC-1295 nor ipamorelin holds a marketing authorisation from the EMA or any comparable regulator, and both are prohibited at all times under WADA.
This page is educational and intended for research and informational use only. It is not medical advice, a treatment recommendation, or dosing guidance, and it makes no promises about outcomes. Where a compound has held a marketing authorisation, approved medicines are supplied only through licensed pharmacies with a prescription. Body Pharm EU supplies research-grade materials for laboratory use, not approved medicines, and nothing here should be read as a substitute for advice from a qualified healthcare professional.
This is the one pairing on the site where the comparison itself is the wrong frame. The two act on different receptors, are used together rather than instead of each other, and arrive in a single pen. The genuinely useful comparison is a different one — and it is between two versions of CJC-1295.
Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab 2006;91(3):799–805. PMID 16352683; Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. JCEM 2006;91(12):4792–7. PMID 17018654; Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139(5):552–61. PMID 9849822
Growth-hormone release from the pituitary has more than one input. GHRH tells the pituitary to release; the ghrelin receptor provides a second, independent trigger.
CJC-1295 works on the first pathway and ipamorelin on the second (what CJC-1295 and ipamorelin are). That is why the literature treats them as complementary rather than competing, and why ranking them for potency is a category error: one amplifies a pulse and the other initiates one. Neither substitutes for the other’s pathway.
Search interest in “CJC-1295 DAC vs no DAC” exceeds interest in either compound alone, and unlike the head-to-head framing, this distinction is real and consequential.
The DAC modification binds the peptide to albumin, stretching its half-life from minutes to days. That sustained elevation is what Teichman et al. measured: GH raised two- to ten-fold for six days or more, IGF-1 by 1.5- to three-fold for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days.
Without DAC, CJC-1295 is essentially modified GRF 1-29 and behaves as a brief pulse-preserving signal — far closer to sermorelin than to the profile above. The two versions share a name and very little else in exposure terms, and any dosing or scheduling figure that does not specify which version it refers to is unusable.
CJC-1295 has placebo-controlled human pharmacology — two randomised trials of 28 and 49 days in healthy adults aged 21 to 61 — and it measured hormone concentrations, not muscle (see what the GH-axis evidence measured for muscle).
Ipamorelin’s characterisation (Raun 1998) is preclinical. It is a pentapeptide identified within a series derived from growth hormone-releasing peptide-1, and its reported advantage is selectivity: it releases GH with less effect on other pituitary hormones than the earlier GHRP compounds. There is no published human dose-ranging trial for it.
No published human trial has administered both compounds together and measured the outcome. The amplify-and-trigger rationale is mechanistic reasoning, not evidence, and combination-specific effects are unrecorded.
The theoretical concern with a long-acting GHRH analogue is that sustained stimulation flattens the natural pulsatile pattern. Ionescu and Frohman examined it directly and reported that pulsatile secretion persists during continuous stimulation. A real answer to a real objection.
Related: growth hormone peptides, dosing in the literature, reported adverse events, peptides for sleep.
We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy